SOPHiA GENETICS (NASDAQ:SOPH) Price Target Raised to $14.00

SOPHiA GENETICS (NASDAQ:SOPH) had its price objective boosted by HC Wainwright from $12.00 to $14.00 in a research note issued to investors on Wednesday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.77) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at ($0.02) EPS, FY2029 earnings at $0.31 EPS and FY2030 earnings at $0.72 EPS.

Several other research analysts have also recently commented on SOPH. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Trading Up 15.2%

Shares of NASDAQ:SOPH opened at $7.71 on Wednesday. The company’s 50-day moving average price is $5.63 and its two-hundred day moving average price is $5.15. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 1.90. SOPHiA GENETICS has a one year low of $2.96 and a one year high of $7.86. The stock has a market capitalization of $646.79 million, a PE ratio of -6.70 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, equities analysts forecast that SOPHiA GENETICS will post -0.77 EPS for the current fiscal year.

Insider Activity

In other news, CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the transaction, the chief executive officer directly owned 670,651 shares in the company, valued at $3,500,798.22. The trade was a 1.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jurgi Camblong sold 50,069 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the sale, the chief executive officer directly owned 3,601,493 shares in the company, valued at approximately $20,888,659.40. The trade was a 1.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 276,092 shares of company stock valued at $1,637,350 in the last quarter. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently bought and sold shares of SOPH. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at approximately $50,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS during the 4th quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.